Dr. Reddy's Laboratories, Fredun Pharmaceuticals and Lemon Tree Hotels to see some action today

18 May 2026 Evaluate

Dr. Reddy's Laboratories has launched its generic Semaglutide Injection in Canada. The company is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates the company’s readiness to ensure patient access following approval.

Fredun Pharmaceuticals has launched ‘DAULCEL’, its premium wellness and longevity-focused brand developed to cater to the growing demand for preventive healthcare, healthy aging, and lifestyle-oriented wellness solutions. The launch marks another strategic step in its expansion into innovation-led and future-focused healthcare segments.

Lemon Tree Hotels has signed Lemon Tree Hotel, Satya Nagar, Bhubaneswar in Odisha. The hotel will be managed by Carnation Hotels, a wholly owned subsidiary of Lemon Tree Hotels. The signing comes immediately after the launch of the company’s second operational hotel in Bhubaneswar, further reinforcing Lemon Tree Hotels’ long-term commitment to the city and confidence in Odisha’s growing hospitality potential.

Texmaco Rail & Engineering has secured two Letters of Acceptance (LoAs) aggregating to Rs 191.99 crore (including taxes) from South Central Railway. The LoAs are for the comprehensive signalling and telecommunication works for provision of Automatic Block Signalling System. The orders are to be executed within 480 days from the appointed date.

Tata Motors has entered into an agreement and acquired around 18% equity stake in Freight Commerce Solutions (Freight Tiger) through secondary purchase from existing shareholders for an aggregate consideration of around Rs 95.66 crore on May 15, 2026. With this acquisition, the company’s connected vehicle platform, ‘Fleet Edge’ together with ‘Freight Tiger’ aspire to forge a comprehensive end-to-end digital ecosystem for the entire logistics value chain, covering both the truck and the trip ecosystem.

Aurobindo Pharma’s wholly owned subsidiary -- CuraTeQ Biologics (CuraTeQ) has received marketing authorisation under Form CT 23 from Central Drugs Standard Control Organization (CDSCO) for Bevqolva, a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The authorisation permits manufacture at CuraTeQ’s facility in Hyderabad and marketing of Bevqolva in 100 mg/4mL and 400 mg/16 mL vial presentations.

Somany Ceramics has received approval for investment of up to Rs 8 crore by way of subscription/acquisition of equity shares in M/s Vintage Tiles (VTPL), an Associate of the Company, in one or more tranches from time to time. The objective of the investment is setting up of solar power plant and upgradation of the existing manufacturing plant. The Board of Directors of the company at their meeting held on May 15, 2026, has approved the same.

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.